Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $16.03 and last traded at $16.25, with a volume of 2375 shares changing hands. The stock had previously closed at $16.67.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on AAPG shares. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price for the company. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $46.43.
Get Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Down 2.8%
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $22.24 million during the quarter. Sell-side analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.
Hedge Funds Weigh In On Ascentage Pharma Group International
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International in the second quarter worth about $391,000. Finally, Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth approximately $383,000.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.
Founded in 2008 by biotechnology entrepreneur Dr.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- TSMC Revenue Jumps 53% in August, Signaling Strong AI Chip Demand
- This AI ETF Is Missing the Biggest AI Winners
- Could Snowflake’s Big Quarter Be a Sign of More to Come?
- Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
